AI Image
McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
Reuters • • business
Key Points:
- Option Care's shares surged 21% in extended trading following reports of a potential acquisition by McKesson, which could be announced as soon as Tuesday, though talks may still fall through.
- The acquisition would align with McKesson's strategy to expand its healthcare services footprint, following its recent $2.25 billion purchase of Precision Medicine Group.
- Analyst Michael Cherny noted the strategic rationale of the deal, highlighting McKesson's expansion beyond physician offices into home and alternate-site care through Option Care's infusion services.
- Option Care specializes in providing intravenous medication infusions at home or outpatient settings, offering an alternative to hospital-based care.
- McKesson has been focusing on reshaping its portfolio by divesting non-core assets and investing in oncology and specialty care, with its oncology & multispecialty segment revenue rising 33% in the latest quarter.
![Apple killed the Mac mini's best hidden feature [Video]](https://media-cdn.cashwalklabs.io/https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fimages.cashwalklabs.io%2F0_admin%2Fnews-ai-images%2F01a11340-c25d-70f7-928a-505357cf3a98.webp?format=webp&w=120&h=80)
